Pill Identifier App

Caniplas (Canada)

This page contains information on Caniplas for veterinary use.
The information provided typically includes the following:
  • Caniplas Indications
  • Warnings and cautions for Caniplas
  • Direction and dosage information for Caniplas

Caniplas

This treatment applies to the following species:
Manufacturer: Plasvacc

CANINE PLASMA

FOR ANIMAL TREATMENT ONLY

Contains normal canine plasma and trisodium citrate anticoagulant at 3 - 4g/L.

Caniplas Indications

May aid in the treatment of various conditions in dogs in which the administration of normal canine plasma would be considered desirable.

DIRECTIONS FOR USE: TO BE USED BY OR UNDER THE SUPERVISION OF A LICENSED VETERINARIAN ONLY.

IMPORTANT: Do not mix with any other substance. Do not transfer to another container. Administer through a blood administration set containing a filter. Avoid volume overload. Complications are very infrequent but may include mild reactions such as tachypnea, tachycardia, restlessness and trembling. If these symptoms become severe, it is advisable to slow the rate of administration or to stop and restart in 5 -10 minutes. If symptoms recur or persist, discontinue administration.

Dosage and Administration

Thaw frozen plasma using only warm water at 95° to 100°F (35° - 38°C), as thawing in microwaves or excessively hot water can damage plasma. Warm to body temperature. Thawed product should be used within 7 days. Do not refreeze thawed product. Store thawed product under refrigeration at 36° - 40°F (3° - 5°C). Administer 1 bag (100mL) per 22lb (10kg) bodyweight by SLOW intravenous infusion (5 - 10mL/kg/hr). Avoid volume overload. Dosage is based on the bodyweight of the plasma recipient, or upon experience resulting from past testing and treatment in similar circumstances.

GENERAL INSTRUCTIONS: This product is frozen immediately after collection and is not pasteurized. As with all plasma products, this product contains an anticoagulant. However it contains no preservatives and donor dogs have been screened to be suitable as plasma donors. Keep plasma frozen until required.

Disposal

Dispose of empty containers, outer packaging or expired product by wrapping with paper and putting in trash. Discarded needles should be immediately placed in a designated “sharps” container. The container should be of a type to reduce the possibility of injury to handlers during collection and disposal. Incineration is the preferred method of disposal; otherwise “sharps” should be buried at a suitable site, away from watercourses.

Storage

Store below 20°F (-5°C) (Freeze).

Precautions

No studies have been performed on the safety of the product in neonates, or its effects on reproductive performance, or administration at more than the recommended dose. Animals which have previously been treated with blood or plasma products, or which have a history of atopy, are more likely to exhibit hypersensitivity reactions following plasma transfusions. Parenteral pre-administration of antihistamines may be useful in reducing the severity of these reactions, should they occur. Minor cross-matching (recipient erythrocytes + Caniplas) should be considered for animals with a history of receiving blood or plasma products. Exceeding the recommended rate of administration may result in signs consistent with fluid overload, such as tachycardia, restlessness and dyspnea. Administration of Caniplas without adequate filtration may result in signs consistent with pulmonary embolism, such as acute dyspnea, cyanosis and acute distress. Administration of inadequately warmed Caniplas may result in hypothermia. Pyrexia associated with administration of the product may indicate platelet incompatibility. Prolonged, immune-mediated thrombocytopenia is a rare sequel to administration of products containing platelets, and is usually self-limiting after a few months. Administration of product containing citrate to animals with compromised hepatic function may result in signs consistent with citrate toxicity and resultant hypocalcemia, tachycardia, trembling, and weakness.

This product is not sourced from SPF animals. Donor dogs are vaccinated against Canine Distemper Virus, Canine Adenovirus 1, Canine Parvorvirus, Canine Parainfluenza Virus, Bordetella bronchiseptica and E. coli endotoxin. The plasma is sourced from adult animals that are clinically healthy, thus lowering the risk of disease transmission.

USER SAFETY INFORMATION: The hazard posed to persons handling the formulation would be equivalent to that posed by handling healthy, vaccinated dogs.

Produced in Australia by Plasvacc Pty Ltd under APVMA GMP Licensing conditions, and imported by:

Plasvacc USA Inc, 1535 Templeton Road, Templeton, CA, 93465, USA

Phone 1800 654 9743, FAX 805 434 2720

Email: usmail@plasvaccusa.com

100 mL, 200 mL

NAC No.: 12530072

PLASVACC USA INC.
1535 TEMPLETON ROAD, TEMPLETON, CA, 93465
Telephone:   805-434-0321
Order Desk:   800-654-9743
Fax:   805-434-2720
Website:   www.foalsbeststart.com
    www.plasvaccusa.com
Email:   usmail@plasvaccusa.com
Every effort has been made to ensure the accuracy of the Caniplas information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-07-28

(web3)